IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

GENENTECH, INC.,)
Plaintiff,)
v.)) C.A. No. 18-924-CFC
AMGEN INC.,)
Defendar	nt.) PUBLIC VERSION FILED: December 2, 2019
)

REPLY BRIEF IN SUPPORT OF GENENTECH'S MOTION TO STRIKE AMGEN'S ELEVENTH AND TWELFTH AFFIRMATIVE DEFENSES (AND DISMISS, OR ALTERNATIVELY, STRIKE ASSOCIATED COUNTERCLAIMS)



TABLE OF CONTENTS

INTR	RODU	CTION	V	1		
ARG	UMEN	VT		3		
I.	Amg	Amgen Was Required To Seek Leave To Add New Defenses				
	A.	The Court's Scheduling Order Required Amgen To Seek Leave To Include Its Defenses				
	B.		Majority View Is To Require Amgen To Seek Leave To Add uses That Exceed The Breadth Of Genentech's Amendments	6		
II.	The Court Should Deny Amgen Leave To Inject An Improper Inventorship Or Derivation Defense Into This Case At This Late Stage					
	A.	Amgen Cannot Establish Good Cause Under Rule 16(b)(4)9				
	B.	Amge	Amgen Also Fails To Meet The Rule 15(a) Standard			
		1.	Amgen Unduly Delayed	.12		
		2.	Amgen's Amendment Would Burden The Court And Unfair! Prejudice Genentech	-		
		3.	Amgen's Proposed Amendment Is Futile	. 15		
III.		The Court Should Deny Amgen Leave To Inject An Improper Inequitable Conduct Defense Into This Case At This Late Stage				
	A.	Amgen Cannot Establish Good Cause Under Rule 16(b)(4)15				
	B.	Amgen Also Fails To Meet The Rule 15(a) Standard				
		1.	Amgen Unduly Delayed	. 17		
		2.	Amgen's Amendment Would Burden The Court And Unfair Prejudice Genentech	ly		
		3.	Amgen's Proposed Amendment Is Futile			
CON	CLUS	ION				




TABLE OF AUTHORITIES

Am. Axle & Mfg., Inc. v. Neapco Holdings LLC, No. CV 15-1168-LPS, 2017 WL 3888228 (D. Del. Sept. 6, 2017)
Cobra Int'l, Inc. v. BCNY Int'l, Inc, 702 F. App'x 994 (Fed. Cir. 2017)
Compagnie Des Grands Hôtels d'Afrique S.A. v. Starwood Capital Group Global I LLC, No. CV 18-654-RGA, 2019 WL 4740083 (D. Del. Sept. 27, 2019)16
Coppola v. Smith, 2015 WL 2127965 (E.D. Cal. May 6, 2015)
In re Frescati Shipping Co., 886 F.3d 291 (3d Cir. 2018), cert. granted sub nom. CITGO Asphalt Ref. Co. v. Frescati Shipping Co., 139 S. Ct. 1599 (2019)11, 12
Johnson v. Mammoth Recreations, Inc., 975 F.2d 604 (9th Cir. 1992)6
Magsil Corp. v. Seagate Tech., No. CV 08-940-HB, 2010 WL 2710472 (D. Del. July 7, 2010)
Patel v. Pandya, 2016 WL 3129615 (D.N.J. June 2, 2016)
Robinson v. Johnson, 313 F.3d 128 (3d Cir. 2002)
Sirona Dental Sys., Inc. v. Dental Imaging Techs. Corp., No. CV 10-288-GMS, 2012 WL 3929949 (D. Del. Sept. 10, 2012)4, 7, 8
Slim CD, Inc. v. Heartland Payment Sys., Inc., 2007 WL 2459349 (D.N.J. Aug. 24, 2007)6
Teva Pharm. USA, Inc. v. Forest Labs., Inc., No. 13-cv-02002-GMS, 2016 WL 7325511 (D. Del. June 16, 2016)
Unigene Labs., Inc. v. Apotex, Inc., 655 F.3d 1352 (Fed. Cir. 2011)



Virginia Innovation Scis., Inc. v. Samsung Elecs. Co.,	
11 F. Supp. 3d 622 (E.D. Va. 2014)	8
Rules	
Fed. R. Civ. P. 8	11
Fed. R. Civ. P. 15	passim
Fed. R. Civ. P. 16(b)	7, 9, 15
Other Authorities	
3 James Wm. Moore et al., Moore's Federal Practice § 15.17[6] (3d ed. 2012)	5



INTRODUCTION

Amgen's new defenses should be stricken because Amgen could have pursued discovery into the facts underlying those defenses well before the deadline for amended pleadings and the close of fact discovery.

Amgen essentially seeks to relitigate this Court's prior ruling rejecting Amgen's effort to pursue that discovery. D.I. 395 at 1, 412 at 1. In denying those requests, the Court rightly noted that the individual Amgen contends was an inventor—Dr. Brian Leyland-Jones—was "in [Amgen's] employ. [Amgen] could have issued ... a litany of subpoenas to depose everybody that he said he had conversations with and worked on in connection with his role in the inventorship but [Amgen] didn't do it. So the application [for discovery] is untimely and therefore, it's denied." See Ex. 1 (Oct. 16, 2019 Hearing Tr.) at 207:4-9. The Court likewise rejected Amgen's reliance on an email authored by one of the named inventors—Dr. Sharon Baughman—which Amgen argued suggested Dr. Leyland-Jones conceived of the invention. Compare D.I. 412 at 1; Ex. 1 at 204:18-205:2 ("[Genentech's Counsel:] She didn't say he was the inventor. . . THE COURT: I agree with you.") with D.I. 456 at 15. Nor did the Court credit Amgen's assertion that it could not have investigated its defenses until it learned of Dr. Baughman's email or took the deposition of one of Genentech's experts, Dr. Karen Gelmon. Compare D.I. 412 at 1-2 with D.I. 456 at 17, 19. The Court



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

